Exenatide News and Research

RSS

Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.

Diabetes medication shows promise in reducing alcohol use

New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat diabetes may be effective in reducing alcohol use.

15 Nov 2024

Rise in weight-management glucose-lowering drug prescriptions in type 1 diabetes patients

From 2010 to 2023, GLP-1RAs and SGLT2 inhibitors saw rising prescriptions in type 1 diabetes, particularly for patients with obesity and cardiorenal risks.

23 Oct 2024

Bariatric surgery outperforms GLP-1 medications in protecting kidney function

A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery was associated with a significant decrease in the progression of chronic kidney disease compared to those who received GLP-1 diabetes medications. The paper was published in Annals of Surgery.

20 Sep 2024

GLP-1 receptor agonists show promise in treating substance use disorders

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.

9 Sep 2024

Semaglutide may reduce smoking risks for diabetes patients

Semaglutide shows promise in reducing tobacco use disorder-related health encounters in patients with type 2 diabetes, but further clinical trials are needed to confirm its efficacy.

29 Jul 2024

GLP-1-based polyagonists: A promising weight loss alternative to bariatric surgery

Researchers highlight the unprecedented success of GLP-1-based multi-receptor drugs in achieving substantial weight loss and improved health outcomes, potentially replacing bariatric surgery for obesity treatment.

28 Jul 2024

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

The advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control.

23 Jul 2024

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Researchers identified distinct hindbrain GLP1R neurons driving satiety and aversion, offering new targets for effective, side-effect-free obesity treatments.

14 Jul 2024

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

A recent review in Diabetes Care evaluates the efficacy and safety of GLP-1 receptor agonists for type 2 diabetes and obesity, exploring their potential for new medical indications.

18 Jun 2024

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.

17 Oct 2023

Revolutionizing type 2 diabetes treatment: personalized approach shows promise in matching patients with optimal glucose-lowering therapies

A personalized therapy selection algorithm for two diabetes type 2 (T2D) treatment drug classes.

10 Aug 2023

Injectable peptide used for type 2 diabetes shows potential for treating 'blinding' IIH headaches

Patients with 'blinding' headaches known as Idiopathic Intercranial Hypertension could be treated with an injectable peptide used for type 2 diabetes, a new trial has found.

13 Mar 2023

Gut hormone receptor polyagonists show promise for obesity and diabetes

A new paper in the Journal of Clinical Investigation describes drugs that could help lose weight and manage type 2 diabetes mellitus (T2DM).

6 Feb 2023

Machine learning and proteomics predict cardiovascular risk more accurately

An innovative proteomics-based model that predicts the risk of cardiovascular events with higher accuracy than current clinical models.

10 Apr 2022

Drug combo for Type 2 diabetes continues to stay effective after two years of treatment

Patients with Type 2 diabetes often take metformin as first-line therapy to help stabilize their blood glucose.

2 Nov 2020

Journal Of Parkinson's Disease announces recipients of first Parkinson Prize

The Journal of Parkinson's Disease and its publisher IOS Press are proud to announce the two articles that have won the first Parkinson Prize, recognizing these outstanding contributions to the advancement to Parkinson's disease research.

23 Jul 2020

Two newer types of diabetes medications show heart and kidney benefits

Two newer types of medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

31 Mar 2020